Chapter Six - Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders

• Autores: Scott D. Kuduk, Christopher J. Winrow, Paul J. Coleman
• Localización: Annual reports in medicinal chemistry, ISSN 0065-7743, Vol 48, 2013, págs. 73-87
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Abstract Since the first identification of the key role of the orexin signaling pathway in regulating sleep/wake and vigilance, a number of drug candidates have entered clinical development targeting the orexin receptors. Among them, suvorexant has been reported to be filed as an New Drug Application (NDA) with the Federal Drug Administration (FDA) in 2012 with the potential to be the first approved orexin receptor antagonist for the treatment of insomnia. A number of additional dual antagonists as well as selective antagonists have been identified to further elucidate the roles of each individual subtype. Beyond sleep disorders, targeting orexin receptors may offer the potential for other therapeutic indications such as migraine, neuropathic pain, depression, anxiety, and addiction.